ImmunityBio Inc (IBRX)

IBRX Chart

Catalysts

News and Press Releases

• ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

  Business Wire | May 23rd

  IBRX
• ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

  Business Wire | April 25th

  IBRX
• ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter

  Seeking Alpha | March 15th

  IBRX
• Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support ImmunityBio's Scaled m-ceNK Clinical Program

  Business Wire | March 2nd

  IBRX
• ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit' in Patients with BCG Unresponsive Bladder Cancer

  Business Wire | February 14th

  IBRX
• ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill' HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

  Business Wire | January 31st

  IBRX
• ImmunityBio's Shares Jump On Encouraging Data From Pancreatic Cancer Immunotherapy Trial

  Benzinga | January 19th

  IBRX
• ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Sur

  Business Wire | January 18th

  IBRX
• Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture

  Benzinga | January 3rd

  AMRSIBRX
• ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat

  Seeking Alpha | December 27th

  IBRX
• ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Phase 3 of COVID T-Cell Universal Boost Vaccine Trial and Provides Update on Bladder C

  Business Wire | December 20th

  IBRX
• ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines

  Business Wire | November 18th

  IBRX
• Amyris, Inc. Reports Third Quarter 2021 Financial Results

  PRNewsWire | November 8th

  AMRSIBRX
• Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine

  Benzinga | November 8th

  AMRSIBRX
• ImmunityBio to Present at the Jefferies London Healthcare Conference

  Business Wire | November 4th

  IBRX

Company Info